Innovate Biopharmaceuticals, Inc. (INNT) Trading at $24.87 after Move Up

June 29, 2018 - By Joshua Cleveland

Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) increased significantly to $24.87. Barchart.com reported it on Jun, 29. It has $638.92M MC. The company’s valuation will be $31.95 million more at $26.11 PT.

For more Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) news announced briefly go to: Globenewswire.com, Globenewswire.com, Nasdaq.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of …” announced on June 13, 2018, “Innovate Biopharmaceuticals Scheduled to Present at the Jefferies Global Healthcare Conference in New York on …” on May 31, 2018, “Innovate Biopharmaceuticals, Inc. added to membership of Russell 3000®, 2000® and the Russell Microcap® Indexes” with a publish date: June 25, 2018, “44 Biggest Movers From Yesterday” and the last “The 3 Best Biotech Stocks of 2018 So Far” with publication date: June 28, 2018.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics.The company has $638.92 million market cap. The Company’s late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease , and nonalcoholic steatohepatitis (NASH).Currently it has negative earnings. The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.